Sources & Key Research — LSD-Assisted Therapy

[1] Liechti, M. E. (2017). Modern clinical research on LSD. Neuropsychopharmacology. Read the study.

[2] Carhart-Harris, R. L. et al. (2016). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences. Read the study.

[3] Tagliazucchi, E. et al. (2016). Increased global functional connectivity correlates with LSD-induced ego dissolution. Current Biology. Read the study.

[4] Holze, F. et al. (2021). Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. Read the study.

[5] Holze, F. et al. (2022). Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. Read the study.

[6] Hofmann, A. (1979). How LSD originated. Journal of Psychedelic Drugs. Read the study.

[7] Nichols, D. E. (2018). Dark classics in chemical neuroscience: lysergic acid diethylamide (LSD). ACS Chemical Neuroscience. Read the study.

[8] Ly, C. et al. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports. Read the study.

[9] Holze, F. et al. (2022). Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biological Psychiatry. Read the study.

[10] Holze, F. et al. (2024). LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up. British Journal of Psychiatry. Read the study.

[11] Robison, R. et al. (2025). Single treatment with MM120 (lysergide) in generalized anxiety disorder: a randomized clinical trial. JAMA. Read the study.

[12] Healio (12 March 2024). FDA grants breakthrough designation to MM120 for generalized anxiety disorder. Read more.

[13] Definium Therapeutics, formerly MindMed (12 August 2026). Positive topline results from Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder. Read more.

[14] Definium Therapeutics (14 September 2026). Positive topline results from Phase 3 Panorama study of DT120 ODT in generalized anxiety disorder. Read more.

[15] HCPLive (23 June 2026). Emerge Phase 3: DT120 shows rapid, durable relief in major depressive disorder. Read more.

[16] Krebs, T. S. & Johansen, P. Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. Journal of Psychopharmacology. Read the review.

[17] Nature Mental Health (2026). Classic psychedelics in obsessive–compulsive disorder: a circuit-based framework. Read the study.

[18] Moreno, F. A. et al. (2026). A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder. Journal of Psychopharmacology. Read the study.

[19] The Beckley Foundation. Ground-breaking LSD microdosing for Alzheimer's study. Read more.

[20] Family, N. et al. (2019). Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers. Psychopharmacology. Read the study.

[21] Lago, M. et al. (2026). Transient multidomain functional improvement in advanced Alzheimer's disease following high-dose psilocybin-containing mushroom administration: a case report. Frontiers in Neuroscience. Read the study.

[22] Özaydın, Y. & Canlan Özaydın, B. (2026). Classical psychedelic microdosing, mood, and cognitive function: an umbrella review with narrative synthesis. Journal of Psychopharmacology. Read the review.

[23] MindBio Therapeutics (13 November 2025). Results from Phase 2B microdosing in depression trial. Read more.

[24] Therapeutic Goods Administration. The Poisons Standard (the SUSMP). Read more.

[25] Therapeutic Goods Administration (2023). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. Read more.

[26] Chandler, A. L. & Hartman, M. A. (1960). Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy. AMA Archives of General Psychiatry. Read the study.